Amgen’s Amjevita, the first biosimilar to Humira (adalimumab) to receive approval by the U.S. Food and Drug Administration, is now available in the U.S. for the treatment of ankylosing spondylitis (AS) and other diseases. While the medication was initially approved in 2016, Amjevita is only now reaching…
Smoking and alcohol consumption are both associated with lower rates of peripheral symptoms in people with spondyloarthritis, which includes ankylosing spondylitis, a new study reports. The findings were somewhat surprising, researchers noted, as smoking has been linked to a greater risk of developing certain rheumatic diseases, and with more…
The ratio of two blood proteins, fibrinogen and albumin, accurately measures inflammation severity with different types of spondyloarthritis (SpA), including ankylosing spondylitis (AS), a study showed. The accuracy of this biomarker closely matched those of standard inflammatory markers used in research and clinical practice. Further studies are needed to…
A year of treatment with bimekizumab was safe and significantly eased symptoms of ankylosing spondylitis (AS) in participants of two Phase 3 clinical trials, regardless of whether they had been treated previously with inhibitors of the pro-inflammatory molecule TNF. “Treatment with bimekizumab resulted in rapid and clinically relevant…
Alvotech has launched a Phase 1 clinical trial to test the safety and efficacy of AVT05, its biosimilar drug candidate to Simponi (golimumab) — being developed for the treatment of ankylosing spondylitis (AS) and other diseases marked by inflammation. The study (NCT05632211) is enrolling more than…
Health Canada has approved a high-concentration formulation of Hadlima (adalimumab-bwwd), a biosimilar to Humira (adalimumab), for treating ankylosing spondylitis (AS) and other diseases. A biosimilar is a medical product designed to be identical — with similar properties, as well as comparable safety and effectiveness — to an…
Some immune T-cells that react to microbial proteins also target normal human proteins in people who carry HLA-B27 variants, the strongest genetic risk factor contributing to ankylosing spondylitis (AS), a study revealed. The shape of the protein fragments targeted by the immune T-cells, whether human or bacterial, was almost…
The biotech company Girihlet will collaborate with Mayo Clinic to develop an algorithm that evaluates the effects of immune-suppressing treatments in patients with ankylosing spondylitis (AS), Girihlet announced. Under the so-called “know-how agreement,” Girihlet will use its proprietary ImmuneScanner technology to monitor changes in immune T-cells…
Pregnant women with axial spondyloarthritis (AxS) are not at an increased risk of preeclampsia, unlike those with other rheumatic conditions, a new study suggests. Using more than 3,000 health records, researchers in Sweden and Denmark evaluated preeclampsia risk in pregnant women with rheumatoid arthritis (RA), AxS, and psoriatic arthritis. “Based…
Platelet counts and blood levels of inflammatory proteins interleukin-23 (IL-23) and interleukin-17 (IL-17) were identified as the strongest potential non-genetic biomarkers of ankylosing spondylitis (AS) in a recent umbrella review study. The study, which looked at 43 previously identified biomarkers, found the evidence was weak for most others. The…
Get regular updates to your inbox.